Polynucleotides encoding proteins having acquired α-galactosidase activity
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Apr 19, 2016
Grant Date -
Feb 13, 2014
app pub date -
Sep 13, 2013
filing date -
May 18, 2007
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention provides a pharmaceutical composition comprising a protein having α-galactosidase activity for treating Fabry disease, which causes no allergic side effect, which is highly stable in blood (plasma) and which can readily be taken up by a cell of an affected organ. The pharmaceutical composition for treating Fabry disease of the invention comprises, for example, a protein which acquires an α-galactosidase activity through alteration of the structure of the active site of wild-type human α-N-acetylgalactosaminidase.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully